Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation

Shadi Yaghi1, Ava L Liberman2, Nils Henninger3

  • 1Department of Neurology, New York Langone Health, 150 55th St Suite 3667, Brooklyn, NY, 11220, USA.

Insights

Small stroke size and significant arterial narrowing are linked to therapeutic anticoagulation levels in atrial fibrillation patients experiencing ischemic stroke. These findings suggest additional stroke mechanisms may need targeting for better prevention.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) increases ischemic stroke risk.
  • Therapeutic anticoagulation is crucial for stroke prevention in AF.
  • Understanding factors influencing anticoagulation status during stroke is vital.

Purpose of the Study:

  • To identify factors associated with therapeutic or supratherapeutic anticoagulation at the time of ischemic stroke in AF patients.
  • To explore the relationship between stroke characteristics and anticoagulation status.

Main Methods:

  • Analysis of data from the Initiation of Anticoagulation after Cardioembolic stroke (IAC) study.
  • Inclusion of AF patients who experienced ischemic stroke while on warfarin.
  • Logistic regression models used to assess associations with anticoagulation status (INR ≥2 vs. <2).

Main Results:

  • 382 AF patients on warfarin with ischemic stroke were analyzed.
  • 58.1% had subtherapeutic anticoagulation (INR <2).
  • Small stroke size (≤10 mL) and significant ipsilateral arterial narrowing (≥50%) were independently associated with therapeutic anticoagulation (INR ≥2).

Conclusions:

  • Small stroke volume and atherosclerosis may indicate competing stroke mechanisms.
  • Targeting these additional mechanisms could improve stroke prevention in AF patients.
  • Further research is needed to optimize stroke prevention strategies.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
209
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
148
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
126